Table 1.
Characteristics of patients of the study
| Patients (n = 26) | n (%)a |
|---|---|
| Gender: male | 21 (80.8) |
| Mean age (years ± SD) | 62 ± 10.7 |
| Comorbidities | |
| Diabetes mellitus | 4 (15.4) |
| Immunosuppression | 5 (19.2) |
| COPD | 8 (30.8) |
| Hypertension | 21 (80.8) |
| Arterial coronary disease | 14 (53.9) |
| Severe renal chronic failure (<30 mL/min) | 1 (3.9) |
| Moderate renal chronic failure (30–60 mL/min) | 7 (26.9) |
| Clinical presentation at entry | |
| Intracavitary PVGI | 18 (69.2) |
| Extracavitary PVGI | 8 (30.8) |
| Early PVGI | 14 (53.9) |
| Late PVGI | 12 (46.2) |
| Fever | 21 (80.8) |
| Local erythema | 15 (57.7) |
| Productive fistula | 14 (53.9) |
| Abdominal pain | 8 (30.8) |
| Septic shock | 6 (23.1) |
| Weight (mean ± SD; kg) | 76.2 ± 11.7 |
| Biological data at entry | |
| Creatinine clearance (mean ± SD; mL/min) | 82.9 ± 33 |
| WBC (mean ± SD; /mm3) | 12,445 ± 5,389 |
| C-reactive protein (mean ± SD; mg/L) | 102 ± 96 |
| Microbiological data | |
| Positive blood sample | 9 (34.6) |
| Positive intraoperative sample | 21 (80.8) |
| No bacterial growth | 5 (19.2) |
| Polymicrobial sample | 5 (19.2) |
| MSSA | 11 (42.3) |
| MRSA | 5 (19.2) |
| CNS | 2 (7.7) |
| Streptococcus sp. | 5 (19.2) |
| Enterococcus faecalis | 2 (19.2) |
| Gram-negative bacilli | 8 (30.8) |
| Fungi | 1 (3.9) |
| Initial treatment option of PGVI | |
| PVGI removed | 17 (65.4) |
| Debridement in situ without prosthetic removal | 6 (23.1) |
| Medical treatment without surgery | 3 (11.5) |
| Outcome | |
| New surgery | 12 (46.2) |
| Previous or concomitant treatment | |
| Previous antibiotic treatment | 16 (61.5) |
| Concomitant treatment with statins | 9 (34.6) |
CNS coagulase-negative staphylococci, COPD chronic obstructive pulmonary disease, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, PVGI prosthetic vascular graft infection, WBC white blood cells
aVaules are presented as n (%) unless otherwise stated